MYOVANT SCIENCES

Redefining Care

FOR WOMEN
FOR MEN
FOR YOU

First Fiscal Quarter 2022 Earnings Conference Call

July 27, 2022

Introduction

Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.

Forward-Looking Statements

This presentation contains forward-looking statements, including without limitation, statements related to: Myovant's financial position, commercial execution success, market leadership, patient impact, and targeted pipeline investments; Myovant's position for its corporate and business development opportunities; potential regulatory submissions and/or approvals and commercial launches; Myovant's business strategies, financial condition and trends, competitive position, potential growth opportunities, and expectations or probabilities for success; the potential benefits and commercial opportunities of ORGOVYX and MYFEMBREE; the expected benefits and success of collaborations with Myovant's partners; the timeline and expectations of the commercial launch of ORGOVYX by Accord in Europe; the timeline and expectations of Myovant's and its partners' regulatory submissions and filings, including the EMA submission for endometriosis by Gedeon Richter and the New Drug Submission to Health Canada for ORGOVYX and MYFEMBREE; the timeline and potential outcome of FDA's ongoing review and labeling discussions for the MYFEMBREE sNDA for endometriosis-associated pain; the timeline and potential outcome of FDA's review of the MYFEBREE sNDA proposing updates to MYFEBREE's USPI based on 2-year data in uterine fibroids; the timeline and expectations of Myovant's new pipeline programs focused on women's health and hormone-sensitive oncology. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future result expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those risks discussed under the heading "Risk Factors" in Myovant's Quarterly Report on Form 10-Q filed on July 27, 2022, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

MYOVANT SCIENCES

Business Update

Dave Marek
Chief Executive Officer
Myovant Sciences, Inc.

Fiscal Q1 2022 Key Highlights

COMMERCIAL PERFORMANCE

- Total revenue of $116.5M, including $41.4M of net product revenue
- ORGOVYX commercial demand volume increased 26% vs. fiscal Q4 2021
- MYFEMBREE continues to expand the GnRH antagonist class and is now the #1 prescribed GnRH therapy for the treatment of uterine fibroids in both NBRx and TRx share in June 2022[1]
- RYEQO now launched in 19 countries by Gedeon Richter since July 2021 European approval

REGULATORY PROGRESS

- In labeling discussions with FDA for on-going review of MYFEMBREE sNDA for endometriosis-associated pain - decision expected by target action date of August 6, 2022
- FDA accepted sNDA proposing updates to MYFEMBREE USPI based on data from the Phase 3 LIBERTY randomized withdrawal study and a set target action date of January 29, 2023
- MHRA approval in June 2022 of ORGOVYX as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in U.K.

BUSINESS DEVELOPMENT & FINANCIAL

- $50M upfront payment from Accord for exclusive license agreement to commercialize ORGOVYX in Europe recognized as revenue in fiscal Q1 2022
- Well-capitalized with cash and committed financing of $400M as of June 30, 2022

NBRx = New to Brand Prescriptions; TRx = Total Prescriptions; FDA = U.S. Food and Drug Administration; sNDA = Supplemental New Drug Application; USPI = United States Prescribing Information; EC = European Commission; MHRA = Medicines and Healthcare products Regulatory Agency

(1) Among GnRH antagonists FDA-approved for uterine fibroids. Data from Symphony Health.

Commercial Update

Lauren Merendino
Chief Commercial Officer
Myovant Sciences, Inc.

ORGOVYX® Performance Update

ORGOVYX, for adults with advanced prostate cancer.
More information including full prescribing information is available at https://www.myovant.com/orgovyx-prescribing-information.pdf

Strong Growth Continues on Multiple Fronts

ORGOVYX® (relugolix) 120 mg tablets

~18,000 Patients

estimated cumulative patients treated since launch[1]

$36.0 Million

net product revenues recorded in fiscal Q1 2022

26% Growth

commercial demand volume vs. fiscal Q4 2021[2]

(1) Through June 30, 2022. ORGOVYX was launched on January 3, 2021. Includes patients on free and commercial drug, excludes patients utilizing product samples.
(2) Account level sales excluding inventory fluctuations at Specialty Distributors and Specialty Pharmacies.

MYOVANT SCIENCES

Substantial Net Sales Growth Quarter Over Quarter

ORGOVYX® (relugolix) 120 mg tablets



- Broad payer coverage continues[1]:
  - Commercial – 81% of lives
  - Medicare Part D – 99% of lives
  - 75% of patients pay less than $60 out of pocket per month[2]
- GTN remains in the low-to-mid 40% range
- Leading growth indicators continue to be strong, including:
  - New patient starts
  - Account growth

GTN = Gross to Net
(1) 2022 MMIT coverage data.
(2) Symphony Health claims analysis.

MYOVANT SCIENCES

Considerable Growth in New Patient Starts; Majority of Patients Early in Disease

ORGOVYX® (relugolix) 120 mg tablets

Estimated Cumulative Patients Treated with ORGOVYX[1]



ORGOVYX Patient Mix[2]



(1) Patient estimates are approximate based on Specialty Pharmacy data extrapolation. Includes patients on free and commercial drug, excludes patients utilizing product samples. In November 2021 ORGOVYX sampling was initiated and free trial enrollment was discontinued.
(2) Symphony Health data; launch through May 2022.

MYOVANT SCIENCES

Broad Adoption and Strong Growth Across All Treatment Settings

ORGOVYX® (relugolix) 120 mg tablets

Fiscal Q1 2022 ORGOVYX Commercial Volume and Volume Growth by Account Type



Account Type	FYQ1 Volume Growth[1]
Dispensing Clinics	+26%
Academic / IDN	+22%
Non-dispensing Clinics	+20%
Other*	+53%
Overall	**+26%**

>2,000 treatment centers to date have utilized ORGOVYX

IDN = Integrated Delivery Network
(1) Versus fiscal Q4 2021.
* Other consists of Veterans Affairs/Federal accounts and other accounts that cannot be readily classified.

MYOVANT SCIENCES

MYFEMBREE®
Launch Update

MYFEMBREE, for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
MYFEMBREE has a **BOXED WARNING for THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS**.
More information including full prescribing information is available at https://www.myovant.com/myfembree-prescribing-information.pdf

#1 Prescribed GnRH Therapy for Uterine Fibroids; Continuing to Drive Class Growth[1]

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

MYFEMBREE continues NBRx Leadership and now is also TRx market leader[1]

~5,800 Patients

cumulative patients treated since launch[2]

51% TRx Share

of GnRH antagonist therapies FDA-approved for uterine fibroids[1]

~180% Class Growth

in TRx for GnRH antagonist therapies FDA-approved for uterine fibroids since MYFEMBREE launch[3]

Fiscal Q1 2022 net revenues of $4.0M

GnRH = Gonadotropin-releasing Hormone; TRx = Total Prescriptions; FDA = U.S. Food & Drug Administration
Data through June 30, 2022;
(1) In June 2022 for total prescriptions among GnRH antagonists FDA-approved for the treatment of uterine fibroids.
(2) Through June 30, 2022. Includes patients on MYFEMBREE free goods programs and commercial volumes. Excludes patients using product samples.
(3) 4-week moving average TRx for GnRH antagonists for uterine fibroids since MYFEMBREE launch in June 2021.

MYOVANT SCIENCES

Strong Growth in New Patient Starts

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

Estimated Cumulative Patients Treated with MYFEMBREE[1]



- ~2,400 new patient starts in fiscal Q1
- 95% of MYFEMBREE patients are new to the GnRH market
- 94% of Commercial lives covered[2]
- 75% of Commercial patients pay $5 or less out of pocket per month on average[2]

GnRH = Gonadotropin-releasing Hormone; TRx = Total Prescriptions
(1) Includes patients on free and commercial drug, excludes patients utilizing product samples. Symphony Health data through June 30, 2022.
(2) Symphony Health claims analysis.

MYOVANT SCIENCES

Market Leadership[1] Driven by Our Clinical Profile and Commercial Strategy

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

Quarterly Exit Share Among GnRH Antagonists FDA-Approved for the Treatment of Uterine Fibroids[2]

New-to-Brand Prescriptions (NBRx)



Total Prescriptions (TRx)



GnRH = Gonadotropin-releasing Hormone; FDA = U.S. Food & Drug Administration; NBRx = New-to-Brand Prescriptions; TRx = Total Prescriptions
Data from Symphony Health.
(1) In new-to-brand and total prescriptions among GnRH antagonists FDA-approved for the treatment of uterine fibroids as of June 2022.
(2) Monthly share at the exit of each quarter for NBRx and TRx shown.
ORIAHNN is a registered trademark of AbbVie Inc.

MYOVANT SCIENCES

Driving Expansion of the GnRH Antagonist Market[1] for Uterine Fibroids

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

4-Week Moving Average TRx for GnRH Antagonists for Uterine Fibroids Since MYFEMBREE Launch[2]



Cumulative MYFEMBREE Prescribers From Launch Through June 2022

61%
of MYFEMBREE prescribers were first-time GnRH antagonist prescribers for uterine fibroids



GnRH = Gonadotropin-releasing Hormone; TRx = Total Prescriptions; FDA = U.S. Food & Drug Administration
TRx data from Symphony Health, through June 30, 2022.
(1) Among GnRH antagonists FDA-approved for the treatment of uterine fibroids.
(2) Incremental growth since June 2021 to March 2022 and June 2022 shown on graph.

MYOVANT SCIENCES

Consumer Campaign Driving Increased Engagement in Patients with Uterine Fibroids*

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

"Perfectly Imperfect Life" multichannel campaign launched mid-June is driving initial awareness and targeted engagement through digital channels



* MYFEMBREE is indicated for the control of heavy menstrual bleeding due to uterine fibroids in pre-menopausal women ≥ 18 years of age. It should not be taken for more than 24 months.

MYOVANT SCIENCES

Significant Unmet Need Remains in Endometriosis

MEDICAL NEED (U.S. WOMEN AGES 15-49)[1-4]



IMPACT

3 in 4

women with endometriosis experience debilitating symptoms[1]

UNMET NEEDS IN ENDOMETRIOSIS[5]

- Effective treatments that deliver relief from the pain associated with endometriosis
- Medical treatment options that reduce repeated surgical procedures
- Treatments with manageable tolerability profiles
- Less reliance on prescription medications to manage pain associated with endometriosis
- Affordable and easy to access treatment options

(1) Bulletti, et al. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441–447.
(2) 2020 US Census Data.
(3) Louis, et al. Incidence of endometriosis by study population and diagnostic method: the ENDO Study. Fertil Steril. 2011;96(2):360-365.
(4) Quaas, et al. On-label and off-label drug use in the treatment of endometriosis. Fertil Steril. 2015.103(3):612-625.
(5) Patient and HCP Market Research.

MYOVANT SCIENCES

Financial Review

Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.

Composition of Total Net Revenues

Unaudited, in millions

	First Fiscal Quarter	
	2022 (ended June 30, 2022)	2021 (ended June 30, 2021)
Product revenue, net:		
ORGOVYX	$ 36.0	$ 10.5
MYFEMBREE	4.0	1.1
Richter product supply and royalties	1.3	—
Total product revenue, net	41.4	11.6
Pfizer collaboration revenue[1]	25.1	29.5
License and milestone revenue[2]	50.0	—
Total net revenues	$ 116.5	$ 41.1

(1) For First Fiscal Quarter 2022, represents partial amortization of the upfront payment ($21.0 million) and of the regulatory milestone payment associated with the FDA approval of MYFEMBREE in uterine fibroids ($4.2 million) received from Pfizer pursuant to the Pfizer Collaboration and License Agreement. For First Fiscal Quarter 2021, represents the partial amortization of the upfront payment ($21.0 million) and of the regulatory milestone payment associated with the FDA approval of MYFEMBREE in uterine fibroids ($8.5 million).

(2) For First Fiscal Quarter 2022, represents the recognition of the upfront payment received from Accord.

MYOVANT SCIENCES

Income Statement Highlights

Unaudited, in millions, except per share data

	First Fiscal Quarter	
	2022 (ended June 30, 2022)	2021 (ended June 30, 2021)
Total net revenues	$ 116.5	41.1
Cost of operations:		
Cost of product revenue	4.9	1.0
Collaboration expense to Pfizer	18.0	5.3
Research and development (R&D)[1]	23.9	30.9
Selling, general and administrative (SG&A)[1]	79.0	61.2
Loss from operations	(9.4)	(57.3)
Net loss	$ (21.2)	(61.7)
Net loss per common share[2]	$ (0.22)	(0.67)

(1) For First Fiscal Quarter 2022, includes $6.0 million and $3.7 million of non-cash share-based compensation (SBC) in SG&A expenses and R&D expenses, respectively. For First Fiscal Quarter 2021 includes $7.2 million and $4.0 million of non-cash SBC in SG&A expenses and R&D expenses, respectively.

(2) Basic and diluted.

MYOVANT SCIENCES

Summary of Cash and Committed Financing

Unaudited, in millions

	June 30, 2022
Total of cash and marketable securities	$ 358.7
Financing available from Sumitomo Pharma	41.3
Total of cash and committed financing from Sumitomo Pharma	$ 400.0

Strong financial position to help deliver on our key growth drivers

MYOVANT SCIENCES

Positioned to Deliver on Key Growth Drivers

Delivering for Today

ORGOVYX – drive continued growth across patient types and treatment settings towards establishing a new standard of care

MYFEMBREE – expand NBRx and TRx market leadership while continuing to grow the class[1]; amplify patient activation efforts

Leverage **strategic partnerships** to expand our patient impact globally

Strong **financial position** fuels successful commercial execution and targeted pipeline investments

While Building for Tomorrow

Support FDA's ongoing review and labeling discussions for the **endometriosis sNDA**; PDUFA August 6, 2022

EMA submission for endometriosis by Gedeon Richter in 2022[2]

New Drug Submission to Health Canada for ORGOVYX and MYFEMBREE in 2022[2]

ORGOVYX commercial launch in Europe by Accord expected in 2022[2]

Support FDA's review of the accepted **MYFEMBREE sNDA** based on 2-year data in uterine fibroids; PDUFA January 29, 2023

Details on **new pipeline programs** focused on women's health and hormone-sensitive oncology in FY2022

NBRx = New-to-Brand Prescription; TRx = Total Prescriptions; GnRH = Gonadotropin-releasing Hormone; FDA = U.S. Food and Drug Administration; sNDA = Supplemental New Drug Application; PDUFA = Prescription Drug User Fee Act; EMA = European Medicines Agency

(1) GnRH antagonist class

(2) Calendar year

Q&A Panel

Myovant Sciences, Inc.

Dave Marek
Chief Executive Officer

Uneek Mehra
Chief Financial & Business Officer

Lauren Merendino
Chief Commercial Officer

Juan Camilo Arjona Ferreira, MD
Chief Medical Officer

MYOVANT SCIENCES

MYOVANT SCIENCES

Redefining Care.
For Women. For Men. For You.

investors@myovant.com